2)

University Grants Committee, GRF: 12100221. 2022/1 - 2024/12. Does upregulating RNF125 expression with luteolin overcome vemurafenib resistance in melanoma? PI.

3)

Health and Medical Research Fund, HMRF: 19200791. 2022/12-2025/5. Ginsenoside Rg3 and Artesunate Synergistically Overcome Sorafenib Resistance in Hepatocellular Carcinoma: Pharmacological Effects and Mechanisms of Action. PI.

4)

National Natural Science Foundation of China (NSFC): 82174029. 2022/1-2025/12.基於miR-142-3p/FAM98A通路研究槐花散抗結直腸癌的機制. PI.

5)

University Grants Committee (GRF): 12100221. 2022/1-2024/12. Does upregulating RNF125 expression with luteolin overcome vemurafenib resistance in melanoma? PI.

6)

Innovation and Technology Commission, ITF: ITS/092/20. 2021/01/01-2022/06/30. Pharmacological studies of ginsenoside Rg3 in treating selective BRAF(V600E) inhibitor-resistant cancers. PI

7)

Science Technology and Innovation Committee of Shenzhen: 基礎研究 (重點項目）JCYJ20200109150719846. 2020/12-2023/11. 基2020N100 逆轉腫瘤耐藥天然產物的篩選及機理研究. PI.

8)

Guangdong Natural Science Foundation, GDNSF: 2021A1515010658. 2021/1-2023/12. 基於白介素1介導的炎症信號通路研究黑豆餾油抗特應性皮炎的作用機制. PI.

9)

Health and Medical Research Fund (HMRF): 18192731. 2021/10-2023/9.  Ranunculi Ternati Radix inhibits STAT3 signaling through upregulating miR-351 to exert anti-melanoma effects. Co-I. （PI：Dr. Fu XQ）

10)

Guangdong Natural Science Foundation, GDNSF: 2020A1515010579. 2020/10 - 2023/9. 基於EGFR/STAT3 信號通路探索白術及其有效成分抗黑色素瘤的機制. 面上項目. Co-I. （PI：Dr. Fu XQ）

11)

Innovation and Technology Commission, ITF: PRP/034/19F. 2020/9-2023/2. Research and development of functional foods based on Ganoderma cultivated in Hong Kong. [6,174,500.97 HKD (including talents and industry matching)]. PI.

12)

Research Grants Council, GRF: 12101519. 2020/1-2022/5. Does atractylenolide I synergize the anti-melanoma effects of MK-8776 by inhibiting cyclin-dependent kinase 2 signaling? PI.

13)

National Natural Science Foundation of China, NSFC: 81903868. 2020/1-2022/12. 基於PDGFR-β/STAT3通路探討芪味丸與5-氟尿嘧啶聯用抗肝癌的機制. 青年项目. （PI：Dr. Zhu PL)

14)

Hong Kong Baptist Uinverstiy, HKBU: RC-FNRA-IG/18-19/SCM/01. 2019/6-2021/5. The Role of Noc3p Dimerization in Eukaryotic DNA Replication. PI.

15)

National Natural Science Foundation of China, NSFC: 81874358. 2019/1-2022/12. 基于miR-34b/MET/β-catenin通路探讨四君子汤与达卡吧嗪合用抗黑色素瘤的机制. PI.

16)

National Natural Science Foundation of China, NSFC: 81803788. 2019/1-2021/12. 基於Hsp90信號通路探索菊花及其有效成分小白菊內酯抗黑色素瘤的作用機制. 青年項目. （PI：Dr. Fu XQ）.

17)

Research Grants Council, GRF: 12102918. 2019/1-2021/6. Does parthenolide overcome vemurafenib resistance by inhibiting heat shock protein 90 in melanoma? PI.

18)

Science Technology and Innovation Committee of Shenzhen：自由探索JCYJ20170817173608483. 2018/01-2019/12. 基于JNK2信号通路研究豨莶草的长期肺毒性机制. PI.

19)

Food and Health Bureau, HMRF: 15163441. 2018/4-2020/3. Regulation of microRNA biogenesis by BRAF/MEK targeted therapy: molecular mechanisms and role in drug resistance. PI.

20)

廣州市對外科技合作計畫項目: 20180710100. 2018/04/01-2020/03/01. 粤港毒性中药饮片炮制规范化研究. [Mainland partner: 廣州市藥材公司中藥飲片廠]. 港方负责人 (Co-I).

21)

2017年度廣東省科技發展專項資金-粵港聯合創新領域: No. 20170506. 2017/01- 2019/12. 嶺南中藥材品質標準及標準物質示範性研究. [Mainland partner: 廣東省藥品檢驗所].香港負責人 (Co-I).

22)

Innovation and Technology Commission, ITF: GHX/002/17GD. 2017/12-2019/12. Preclinical Study of the Category I Antitumor New Drug EN-002 Inhibiting the Novel Targets -- DNA Replication Initiation Proteins. PI. 

23)

珍卡儿药妆有限公司，2017/11-2022/11，在香港浸会大学建立“珍卡儿中医透皮治疗实验室”. PI. External

24)

FRG2/17-18/032. 2018/4-2019/3. Elucidating the involvement of Hsp90 in the anti-melanoma effects of parthenolide. PI. 

25)

FRG1/16-17/048. 2017/7-2018/6. Elucidating the role of TRBP down-regulation in acquired resistance of BRAF inhibitor-treated melanoma cells. PI.

26)

FRG2/16-17/033. 2017/3-2017/11. Evaluating the involvement of miR-34b in the anti-melanoma action of Si-Jun-Zi-Tang. PI.

27)

NSFC: 面上項目81673649. 2017/1-2020/12.基於let-7/IGF1R探索槐花金銀酒抗 黑色素瘤的機制. Exploring the let-7/IGF1R-related mechanism of action for the anti-melanoma effects of a herbal formula Huai Hua Jin Yin Jiu. PI.

28)

ITF: UIT/135. 2016/10-2019/10. Study on the pharmacological effects and mechanism of action of Young Yum Pill. PI.

29)

ITF: UIM/290. 2016/09-2018/08. Research on the Second Development of Yi-Shen-Hua-Shi Granules. PI. [Mainland partner: 廣州市藥材公司中藥飲片廠]

30)

Research Grants Council: GRF 12125116. 2016/12-2018/11. Elucidating the role of TLR4/STAT3 signaling in the antimelanoma effects of atractylenolide II. PI.

31)

2017年度廣東省科技發展專項資金-粵港聯合創新領域: No. 2017A050506007. 2017/07–2019/06. 一種新型經鼻腦靶向抗AD石蒜生物鹼納米載藥體系研究. 香港負責人. [Mainland partner: 深圳市老年醫學研究所]

32)

2017年度廣東省科技發展專項資金-粵港聯合創新領域: No. 20170506. 2017/01- 2019/12. 嶺南中藥材品質標準及標準物質示範性研究. 香港負責人. [Mainland partner: 廣東省藥品檢驗所]

33)

HMRF: HKBU14150571. 2017/9-2019/8. Elucidating the involvement of IL-17-IL-6-STAT3 axis in the anti-melanoma effects of a herbal formula comprising Flos Sophorae and Flos Lonicerae. PI.

34)

Science Technology and Innovation Committee of Shenzhen：學科佈局JCYJ20160229210327924. 2016/07-2019/06. 靶向TLR4信號通路的抗類風濕性關節炎中藥研究. PI.

35)

廣東省自然基金： 面上項目2016A030313007. 2016/06-2019/06. miR-34b在四君子湯抑制黑色素瘤生長中的作用研究. PI.

36)

FRG1/15-16/050. 2016/06-2017/05. Investigating the IL-17-IL-6-STAT3 axis-related mechanism of action for the anti-melanoma effects of a herbal formula comprising Flos Sophorae and Flos Lonicerae. PI.

37)

FRG2/15-16/020. 2016/04-2017/03. Elucidating the involvement of interleukin-17 in the anti-arthritic effects of a formula comprising Rosae Multiflorae Fructus and Lonicerae Japonicae Flos. PI.

38)

ITF: UIM/273. 2015/09-2017/08. Study on the Preparation, Safety and Efficacy in Liver Cancer Prevention/Treatment of the Triterpene-enriched Extract from Antrodia Camphorate Mycelia. PI.

39)

FRG2/14-15/056. 2015/04-2016/03. Does quercetin reprogram the melanoma immune microenvironment? PI.